Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Ah-Rong, Nam"'
Autor:
Hyunkyung Park, Ju‐Hee Bang, Ah‐Rong Nam, Ji Eun Park, Mei Hua Jin, Yung‐Jue Bang, Do‐Youn Oh
Publikováno v:
Cancer Medicine, Vol 9, Iss 1, Pp 43-51 (2020)
Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresect
Externí odkaz:
https://doaj.org/article/1e99b3ed25284e7c94bcc8069ffa1118
Autor:
Hye-Rim Seo1,2, Ah-Rong Nam1, Ju-Hee Bang1, Kyoung-Seok Oh1, Jae-Min Kim1,2, Jeesun Yoon3, Tae-Yong Kim1,3, Do-Youn Oh1,2,3 ohdoyoun@snu.ac.kr
Publikováno v:
Cancer Research & Treatment. Apr2022, Vol. 54 Issue 2, p541-553. 13p.
Autor:
Yung-Jue Bang, Do-Youn Oh, Tae-You Kim, Seock-Ah Im, Sae-Won Han, Tae-Yong Kim, Kyung-Hun Lee, Mei Hua Jin, Ju-Hee Bang, Ji Eun Park, Ji-Won Kim, Ah-Rong Nam
Supplementary Table 1. The IC50 values of bosutinib, gemcitabine, and cisplatin in biliary tract cancer cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a263bd7087e0f48f7497024db2dfb5
https://doi.org/10.1158/1535-7163.22507671
https://doi.org/10.1158/1535-7163.22507671
S1- basal expression level S2- MTT Assay and Colony Forming Assay S3- Combination data S4- Trastuzumab monotherapy in vivo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac53aa7854aea7837500dded39fb4917
https://doi.org/10.1158/1535-7163.22504834.v1
https://doi.org/10.1158/1535-7163.22504834.v1
Trastuzumab in combination with chemotherapy is the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-positive breast and gastric cancers. Several resistance mechanisms against anti-HER2 therapy have been proposed. Sr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc32bb8ff3297cc9ab5e836806f550eb
https://doi.org/10.1158/1535-7163.c.6537865.v1
https://doi.org/10.1158/1535-7163.c.6537865.v1
Autor:
Kyoung Seok Oh, Hye Rim Seo, Jae-Min Kim, Ah Rong Nam, Tae Yong Kim, Ju Hee Bang, Mei Hua Jin, Do Youn Oh, Jeesun Yoon
Publikováno v:
Cancer Letters. 516:38-47
Olaparib, a potent PARP inhibitor, has been shown to have great anti-tumor effects in some tumor types. Although biliary tract cancer (BTC) is a good candidate for DNA damage response (DDR)-targeted agents, targeted DDR inhibitors, including olaparib
Autor:
Kyoung-Seok Oh, Ah-Rong Nam, Ju-Hee Bang, Yoojin Jeong, Sea Young Choo, Hyo Jung Kim, Su In Lee, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Banyoon Cheon, Hyunju Cha, John Kim, Do-Youn Oh
Publikováno v:
Cancer Research. 83:4496-4496
Background: PARP inhibitors have shown antitumor activities against solid tumors with HRD (homologous recombination deficiency). The definition of HRD and other potential biomarkers besides HRD should be further evaluated for PARP inhibitors. JPI-547
Autor:
Ah Rong Nam, Jeesun Yoon, Kyoung-Seok Oh, Jae-Min Kim, Ju-Hee Bang, Yoojin Jeong, Sea Young Choo, Hyo Jung Kim, Su In Lee, Tae-Yong Kim, Do-Youn Oh
Publikováno v:
Cancer Research. 83:3872-3872
Background: HER2 (Human epithelial growth factor receptor 2)-targeting therapies have been approved for patients with HER2-positive breast and gastric cancer and use have been attempted in various solid tumor types, including biliary tract cancer. Ho
Autor:
Ah-Rong Nam1, Mei-Hua Jin1, Ju-Hee Bang1, Kyoung-Seok Oh1, Hye-Rim Seo1, Do-Youn Oh1,2 ohdoyoun@snu.ac.kr, Yung-Jue Bang1,2
Publikováno v:
Cancer Research & Treatment. Jul2020, Vol. 52 Issue 3, p945-956. 12p.
Autor:
Mei Hua Jin1, Ah-Rong Nam1, Ji Eun Park1, Ju-Hee Bang1, Yung-Jue Bang1,2, Do-Youn Oh1,2 ohdoyoun@snu.ac.kr
Publikováno v:
Cancer Research & Treatment. Jan2020, Vol. 52 Issue 1, p149-166. 18p.